Wall Street Analysts Predict a 38.07% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should Know [Yahoo! Finance]
Kiniksa Pharmaceuticals, Ltd. - Class A (KNSA)
Last kiniksa pharmaceuticals, ltd. - class a earnings: 8/12 04:02 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $28 indicates a 38.1% upside potential. The mean estimate comprises four short-term price targets with a standard deviation of $3.27. While the lowest estimate of $24 indicates an 18.3% increase from the current price level, the most optimistic analyst expects the stock to surge 57.8% to reach $32. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice. However, an impressive consensus price target is not the only factor that indicates a potential upside i
Show less
Read more
Impact Snapshot
Event Time:
KNSA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNSA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNSA alerts
High impacting Kiniksa Pharmaceuticals, Ltd. - Class A news events
Weekly update
A roundup of the hottest topics
KNSA
News
- Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care ConferenceGlobeNewswire
- Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $34.00 price target on the stock.MarketBeat
- Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its price target raised by analysts at JPMorgan Chase & Co. from $26.00 to $30.00. They now have an "overweight" rating on the stock.MarketBeat
- Analyst Estimates: Here's What Brokers Think Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) After Its First-Quarter Report [Yahoo! Finance]Yahoo! Finance
- Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) had its price target raised by analysts at Evercore ISI from $25.00 to $30.00. They now have an "outperform" rating on the stock.MarketBeat
KNSA
Earnings
- 4/23/24 - Miss
KNSA
Sec Filings
- 5/7/24 - Form 4
- 4/30/24 - Form 4
- 4/25/24 - Form 10-Q
- KNSA's page on the SEC website